2025 ASCO Genitoüriner Kanserler Sempozyumu uzman, En son klinik ve bilimsel konulara multidisipliner bakış açıları alanındaki ilerlemeler.
E-Broşürde Belirtilen Benzersiz Erişim URL'nize bakın. Access 2025 ASCO Genitoüriner Kanserler Sempozyumu
Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.
Dr Neeraj Agarwal, MD, FASCO
Huntsman Cancer Institute at the University of Utah
The Future of Biomarkers in Renal Cell Carcinoma
Dr Samra Turajlic, MD, PhD
The Francis Crick Institute
